Skip to content

Clinical Study on the Efficacy of Pricking and Cupping Therapy at Shu Points in Alleviating Skin Toxicity Caused by EGFR-TKIs in Pulmonary Adenocarcinoma Patients with Damp-Heat and Toxin Stagnation Syndrome

Clinical Study on the Efficacy of Pricking and Cupping Therapy at Shu Points in Alleviating Skin Toxicity Caused by EGFR-TKIs in Pulmonary Adenocarcinoma Patients with Damp-Heat and Toxin Stagnation Syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001893
Enrollment
Unknown
Registered
2025-10-15
Start date
2025-12-31
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

skin toxicity caused by EGFR - TKIs in lung adenocarcinoma

Interventions

Control group:Topical hydrocortisone ointment and/or erythromycin ointment
Treatment group:Topical hydrocortisone ointment and/or erythromycin ointment + back-shu acupoint pricking and cupping therapy

Sponsors

First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Patients with confirmed pathological diagnosis of malignant lung tumor and EGFR gene exon 19/21 mutations. (2) Aged 18-80 years (inclusive). (3) Patients currently undergoing EGFR-TKIs therapy who have developed drug-related rash. (4) Expected survival period = 3 months. (5) Patients diagnosed with the damp-heat toxin stagnation syndrome pattern. (6) Without severe cardiac hepatic or renal dysfunction. (7) No intellectual disabilities or mental disorders; normal verbal expression ability. (8) Fully understand and voluntarily agree to participate in this clinical study having signed the written informed consent form

Exclusion criteria

Exclusion criteria: (1) Patients with severe cardiovascular or hematopoietic system diseases other severe primary diseases or mental illnesses. (2) Patients currently undergoing hormone therapy or antibiotic treatment. (3) Patients uncooperative during the treatment period (i.e. unable to cooperate to complete all clinical observations). (4) Patients who have recently participated in other clinical trials involving acupuncture. (5) Women who are pregnant planning pregnancy or lactating. (6) Patients with severe needle phobia or blood phobia who cannot tolerate the procedure. (7) Patients planning to undergo acupuncture pricking therapy bloodletting cupping therapy or other disease-related treatments and clinical research trials within the 3-month study participation period.

Design outcomes

Primary

MeasureTime frame
Acne-like rash grading score;

Secondary

MeasureTime frame
Recurrence rate of rash;Hamilton Depression Scale;Acne Specific Quality of Life;Total effective rate of rash improvement;Hamilton Anxiety Scale;Karnofsky Performance Status ;

Countries

China

Contacts

Public ContactYang Hongli

First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

787930875@qq.com15022695720

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026